Patent ID: 8454998

Claim:
A method for the symptomatic treatment of a movement disorder selected from a group consisting of Parkinson's disease, secondary parkinsonism, postencephalitic parkinsonism, symptomatic parkinsonism, and injury to the nervous system by carbon monoxide or managanese intoxication comprising administering to a patient an effective amount of a controlled release oral solid formulation of levodopa, (i) wherein the controlled release oral solid formulation of levodopa is a multiparticulate, controlled release oral solid formulation of levodopa comprising (a) a controlled release component comprising levodopa, carbidopa and one or more rate controlling excipients; (b) an immediate release component comprising levodopa and carbidopa, and (c) a carboxylic acid component comprising (1) a carboxylic acid that is not levodopa or carbidopa and (2) one or more rate controlling excipients, wherein the carboxylic acid component is a distinct component and is coated with an enteric polymer; and wherein the controlled release component (a), the immediate release component (b) and the carboxylic acid component (c) comprise beads or granules.